FDA Grants Fast Track, Breakthrough Therapy Designations to Cretostimogene Grenadenorepvec for NMIBC

The FDA has granted fast track and breakthrough therapy designations to cretostimogene grenadenorepvec for use as a potential therapeutic option in patients with high-risk BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 tumors.

Related Keywords

United States ,Chicago ,Illinois ,American ,Ambaw Bellete ,Cg Oncology Inc ,American Urological Association Annual Meeting ,Meeting Of The Society Urological Oncology ,Bacillus Calmette Gu ,Annual Meeting ,Urological Association Annual Meeting ,Accessed January ,Cafda ,Fast Track And Breakthrough Therapy Designations ,Cretostimogene Grenadenorepvec ,Patients With High Risk Bcg Unresponsive Non Muscle Invasive Bladder Cancer Carcinoma In Situ Or Without Ta T1 Tumors ,Bond 003 Study ,